CANY
PRLD icon

Caxton Associates (New York)’s Prelude Therapeutics PRLD Stock Holding History

Caxton Associates (New York)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65,453
Closed -$395K – 605
2022
Q4 		$395K Sell
65,453
-20,539
-24% -$132K 0.03% 286
2022
Q3 		$568K Buy
85,992
+2,125
+3% +$14.3K 0.08% 215
2022
Q2 		$438K Buy
+83,867
New +$427K 0.04% 306

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s PRLD Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 65,453 shares — an estimated $395K sold.

Caxton Associates (New York) first reported a position in PRLD in Q2 2022 and held it in 3 quarters. The position peaked at $568K in Q3 2022. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 65,453 Prelude Therapeutics shares in Q1 2023, an estimated $395K.
  • Caxton Associates (New York) first reported a position in Prelude Therapeutics in Q2 2022 and held it in 3 quarters.
  • Caxton Associates (New York)'s Prelude Therapeutics position peaked at $568K in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.